An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

Second, it focuses on the risks, precautions and complications of the use of TNF-α inhibitors in these patients. Both animal and human studies concerning the role of TNF-α in IMIDs have led to ...

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025 ...

BALTIMORE, April 16, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

During his presentation, Dr. Glass spoke about the Company’s small-molecule TNF-alpha (TNF-α) inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines ...

During his presentation, Dr. Glass spoke about the Company’s small-molecule TNF-alpha (TNF-α) inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines associated ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.